Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 165 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Modifying PEST for Psoriatic Arthritis Screening

 		Plaque Psoriasis, Psoriatic Arthritis Na Canada NCT06382051

LATAM LOWERS LDL-C

 		Hypercholesterolaemia Phase4 Argentina
Brazil 		NCT06501443

Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

 		Hidradenitis Suppurativa Phase3 Canada
United States 		NCT06840392

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

 		Generalized Myasthenia Gravis Phase3 United States NCT06744920

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

 		Chronic Myeloid Leukemia (CML) Phase2 France NCT06514534

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

 		Familial Hypercholesterolemia - Homozygous Phase3 China
United States 		NCT06597006

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

 		Breast Neoplasms Germany NCT06830720

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever

 		Dengue Phase2 Brazil
India
Malaysia
Singapore
View All
 NCT06006559

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

 		Prostate Cancer Phase2, Phase3 Singapore NCT06780670

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

 		Progressive Multiple Sclerosis Phase1, Phase2 Australia
Canada
Switzerland 		NCT06675864